Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, December 10, 2013 LONDON, December 10, 2013 /PRNewswire/ -- On Monday, December 09, 2013, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,808.37, up 0.18%; the Dow Jones Industrial Average closing at 16,025.53, up 0.03%; and the NASDAQ Composite finishing at 4,068.75, up 0.15%. The S&P 500 Health Care Sector Index gained 0.19% to close at 638.95; and the S&P 500 Biotechnology Industry Index closed 0.50% higher at 2,796.27; and the same has surged 9.77% in the previous one month and 12.52% in the last three months, outperforming the S&P 500, which has gained 2.13% and 8.17% during the respective periods. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index edged 0.14% higher to close at 490.41. The major movers in the industry included Hospira Inc. (NYSE: HSP), Alkermes PLC (NASDAQ: ALKS), Theravance Inc. (NASDAQ: THRX), and Celsion Corp. (NASDAQ: CLSN). AAAResearchReports.com initiated preliminary technical research on HSP, ALKS, THRX, and CLSN. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ Hospira Inc.'s stock rose 1.49% on Monday, closing the day at $42.19, after oscillating between $41.65 and $42.50 during the trading session. A total of 1.16 million shares were traded, which is above the daily average volume of 0.81 million. The company's shares have advanced 4.92% in the previous three trading sessions and 8.49% in the last one month, outperforming the S&P 500, which has gained 0.87% and 2.13% during the respective periods. Moreover, Hospira Inc.'s stock is trading near its 52-week high of $42.60 and also above its 50-day and 200-day moving averages of $39.99 and $36.89, respectively. The free technical analysis on HSP is available by signing up at: http://www.AAAResearchReports.com/HSP121013.pdf Alkermes PLC's stock edged 0.23% higher on Monday, tracking gains in the broader market. The company's shares finished the day at $39.94, after vacillating between $39.67 and $40.25 during the trading sessions. A total of 1.15 million shares were traded, which is above the daily average volume of 0.85 million. The company's shares have surged 16.55% in the previous three months and 10.58% in the last one month, outperforming the S&P 500, which has gained 8.17% and 2.13% during the respective periods. Furthermore, Alkermes PLC's stock is trading above its 50-day and 200-day moving averages of $35.81 and $31.06, respectively. Register now to download free research on ALKS at: http://www.AAAResearchReports.com/ALKS121013.pdf Shares in Theravance Inc. fell 2.52% on Monday, ending the day at $36.40, after fluctuating between $36.26 and $38.30 during the trading session. A total of 2.05 million shares were traded, which is above the daily average volume of 0.93 million. Despite Monday's pullback, the company's shares have advanced 5.14% in the last one month, outperforming the S&P 500, which has gained 2.13% during the same period. Additionally, Theravance Inc.'s stock is trading above its 200-day moving average of $34.45. A free report on THRX can be accessed by registering at: http://www.AAAResearchReports.com/THRX121013.pdf Celsion Corp.'s ended the day 2.60% lower at $3.75 on Monday, even as the US equity market advanced. The company's shares fluctuated between $3.70 and $3.84 during the trading session. A total of 0.19 million shares were traded, which is below the daily average volume of 0.41 million. The company's shares have declined 4.34% in the previous three trading sessions, underperforming the S&P 500, which has gained 0.87% during the same period. Further, Celsion Corp.'s stock is trading below its 50-day and 200-day moving averages of $4.58 and $5.01, respectively. Register with AAA Research Reports and download research on CLSN for free at: http://www.AAAResearchReports.com/CLSN121013.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org
Morning Research Covering Healthcare Sector: Hospira, Alkermes, Theravance, and Celsion
Press spacebar to pause and continue. Press esc to stop.